Roche Diagnostics (Hong Kong) Limited
Hong Kong MDACS174 represented devices9 applicantsDec 11, 2007 – Oct 16, 2024
VerifiedMDD (Medical Device Division) · MDACS registry
174
Total devices
9
Applicants
2007
First representation
2024
Most recent
AR overview
- Authorised representative (EN)
- Roche Diagnostics (Hong Kong) Limited
- Phone
- 24813387
Timeline
- First representation
- Dec 11, 2007
- Most recent
- Oct 16, 2024
Regulatory footprint
Search Roche Diagnostics (Hong Kong) Limited across other regulatory registries
Risk class distribution
D17
B83
C63
II11
Applicant partnerships
Top manufacturers represented by this AR
Roche Diagnostics GmbH
143 devices
Roche Molecular Systems, Inc.
17 devices
Roche Diabetes Care GmbH
5 devices
Ventana Medical Systems, Inc.
3 devices
SD Biosensor, Inc.
2 devices
Roche Diagnostics GmbH (Diabetes Care)
1 devices
Roche Diagnostic GmbH
1 devices
HTL-STREFA S.A.
1 devices
Ventana Medical Systems Inc
1 devices
Recent registrations
Latest 15 MDACS listings represented by Roche Diagnostics (Hong Kong) Limited
IVD Test Reagent/Kits, Microbiology, Virus, Identification, Herpes Simplex
体外诊断检测试剂/试剂盒, 微生物学, 病毒, 鉴定, 单纯疱疹病毒
Oct 16, 2024
- Risk class
- C
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Immunoassay, Protein, Complement Component, C3/C3c
体外诊断检测试剂/试剂盒, 免疫测定, 蛋白质, 补体成分, C3/C3c
Oct 16, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Immunocytochemistry/Immunohistochemistry
体外诊断检测试剂/试剂盒, 免疫细胞化学/免疫组化
Oct 16, 2024
- Risk class
- B
- Applicant
- Ventana Medical Systems, Inc.Ventana Medical Systems,Inc.
IVD Test Reagent/Kits, Immunoassay, Protein, Alpha-1-Antitrypsin
体外诊断检测试剂/试剂盒, 免疫检测, 蛋白质, α-1-抗胰蛋白酶
Oct 16, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Serology, Virus, Severe Acute Respiratory Syndrome Coronavirus 2, Antibody
体外诊断 检测试剂/试剂盒, 血清学, 病毒, 严重急性呼吸综合征冠状病毒 2, 抗体
Oct 16, 2024
- Risk class
- C
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Clinical Chemistry, Enzyme, Lactate Dehydrogenase, Isoenzyme
体外诊断检测试剂/试剂盒、临床化学、酶、乳酸脱氢酶、同工酶
Oct 16, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Immunoassay, Protein, Immunoglobulin A
体外诊断 测试试剂/试剂盒、免疫测定、蛋白质、免疫球蛋白A
Oct 16, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Immunocytochemistry/Immunohistochemistry, Stain
体外诊断检测试剂/试剂盒, 免疫细胞化学/免疫组化, 染色
Oct 16, 2024
- Risk class
- B
- Applicant
- Ventana Medical Systems IncVentana Medical Systems,Inc.
IVD Test Reagent/Kits, Serology, Virus, Hepatitis C
体外诊断检测试剂/试剂盒, 血清学, 病毒, 丙型肝炎
Oct 16, 2024
- Risk class
- D
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Panels, Human Genetics, Immunodeficiency, Primary Antibody Deficiency
体外诊断面板, 人类遗传学, 免疫缺陷, 原发性抗体缺乏症
Oct 16, 2024
- Risk class
- B
- Applicant
- Ventana Medical Systems, Inc.Ventana Medical Systems,Inc.
IVD Panels, Human Genetics, Immunodeficiency, Primary Antibody Deficiency
体外诊断面板, 人类遗传学, 免疫缺陷, 原发性抗体缺乏症
Oct 16, 2024
- Risk class
- C
- Applicant
- Ventana Medical Systems, Inc.Ventana Medical Systems,Inc.
IVD Test Reagent/Kits, Immunocytochemistry/Immunohistochemistry, Tumor Marker, PD-L1
体外诊断检测试剂/试剂盒, 免疫细胞化学/免疫组化, 肿瘤标志物, PD-L1
Sep 24, 2024
- Risk class
- C
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Immunoassay, Vitamin, Folate
体外诊断 测试试剂/试剂盒、免疫测定、维生素、叶酸
Sep 24, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Clinical Chemistry, Rapid Test, Urine
体外诊断 检测试剂/试剂盒, 临床化学, 快速检测, 尿液
Sep 24, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
IVD Test Reagent/Kits, Immunoassay, Endocrine Hormone, Growth Hormone
体外诊断 测试试剂/试剂盒,免疫测定,内分泌激素,生长激素
Sep 24, 2024
- Risk class
- B
- Applicant
- Roche Diagnostics GmbHRoche Diagnostics Gmbh
About this profile
Roche Diagnostics (Hong Kong) Limited serves as the authorised representative for 174 medical devices in Hong Kong's MDACS framework. Analyse applicant partnerships, risk class exposure, and recent regulatory activity to understand their market footprint.